2021
DOI: 10.1097/ccm.0000000000005066
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: OBJECTIVES: Four peer-reviewed publications have reported results from randomized controlled trials of convalescent plasma for coronavirus disease 2019 infection; none were conducted in the United States nor used standard plasma as a comparator. To determine if administration of convalescent plasma to patients with coronavirus disease 2019 increases antibodies to severe acute respiratory syndrome coronavirus 2 and improves outcome. DESIGN: Double-blind … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
74
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 60 publications
(77 citation statements)
references
References 22 publications
3
74
0
Order By: Relevance
“…The supplementary data present the assessment of risk of bias of the included studies for each outcome. Twelve trials5054566065677286 proved at low risk of bias for all domains. All other studies proved at probably high or high risk of bias for at least one domain.…”
Section: Resultsmentioning
confidence: 96%
See 1 more Smart Citation
“…The supplementary data present the assessment of risk of bias of the included studies for each outcome. Twelve trials5054566065677286 proved at low risk of bias for all domains. All other studies proved at probably high or high risk of bias for at least one domain.…”
Section: Resultsmentioning
confidence: 96%
“…After screening 52350 titles and abstracts and 1029 full texts, 47 unique randomised controlled trials that evaluated antiviral antibody or cellular treatments were identified as of 21 July 2021 (fig 1). 43444546474849505152535455565758596061626364656667686970717273747576777879808182838485868788 A table of excluded full texts is provided in the supplementary data on bmj.com. Searches of living evidence retrieval services identified 11 publications of eligible randomised trials, which were reconciled with our formal search strategy when necessary 222324254549566466676875838688.…”
Section: Resultsmentioning
confidence: 99%
“…These studies include a powerful RCT in elderly outpatients that halved progression to severe disease. 13 In the USA, the two completed RCTs each show a reduction of mortality with CPP usage (Bennett-Guerrero et al, 2021;O'Donnell et al, 2021). Second, convalescent plasma has proven effective in individuals with defective humoral immunity and B cell defects (Senefeld et al, 2020;Thompson et al, 2021).…”
Section: Discussionmentioning
confidence: 99%
“…Severely affected patients were the focus of early studies and initial clinical trials of potential treatments, in part due to immediate logistics and ethical considerations. Many potentially promising studies were stopped for futility because treatments with anti-inflammatory or anti-coagulant therapies at late stages of COVID-19 were not effective 91 , 92 , 93 , 94 , 95 , 96 . Secondary analysis of some of these trials showed modest effects on those with less severe symptoms, indicating that treating earlier in the disease progression might prove more efficacious 91 .…”
Section: Case Reportsmentioning
confidence: 99%